Brooks Laboratories has reported a consolidated net profit of ₹1.52 crore for the quarter ending March 2026, marking a recovery from a net loss of ₹1.46 crore during the same quarter in the previous year. Despite this positive turnaround in profitability, the company experienced a 13.34% decline in sales, which totaled ₹20.21 crore, down from ₹23.32 crore in March 2025. For the full fiscal year ending March 2026, Brooks Laboratories achieved a net profit of ₹24.58 crore, a notable improvement compared to a net loss of ₹9.97 crore in the prior year. Sales for the year rose by 3.85%, reaching ₹85.74 crore, compared to ₹82.56 crore in the previous fiscal year. The operating profit margin (OPM) for the quarter was reported at 3.32%, a decrease from 5.36% in the same quarter last year. The profit before tax (PBT) for the quarter was also positive at ₹1.52 crore, contrasting with a loss of ₹1.28 crore in the corresponding quarter of the previous year. This mixed financial performance indicates both challenges and recoveries for Brooks Laboratories.